• The company had more than 40 sales offices and over 25 manufacturing plants in India, 11 approved by USFDA. • Earned pre-tax profits of 23% in 2010 and enjoyed average annual growth rate of 22% from 2000-10. CIPLA’s future strategy • Will focus more on allied work and build public relations. • Focus on growing area of its businesslike exporting patent –expired pharmaceuticals. • Tieing up with MNC’s to generate third-line drug for
Company Overview The Aditya Birla Group is a multinational conglomerate named after Aditya Vikram Birla, headquartered in the Aditya Birla Centre in Worli, Mumbai, India. It operates in 40 countries with more than 120,000 employees worldwide. The group was founded by Seth Shiv Narayan Birla in 1857. The group interests in sectors such as viscose staple fiber, metals, cement (largest in India), viscose filament yarn, branded apparel, carbon black, chemicals, fertilizers, insulators, financial services, telecom (third largest in India), BPO and IT services. The group had revenue of approximately US$45 billion in year 2014.
The agreement so entered by the competitors must have an appreciable effect on the market so as to qualify itself for being restricted by the competition law. Some of the parameters to judge the effect of the agreement on the market are as follows: • The aggregate of business that is being controlled by the competitors. • The remaining strength of the
The Indian pharmaceuticals market stands third in terms of volume and 14th largest in terms of value. In the Global Pharmaceutical Industry the total production of the sector is 20% in terms of vol. and 1.4% in terms of value. India is the leading supplier of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume . One of the major characteristics of this industry is that it is highly fragmented.
In the rest of the world markets, it has a strong ground network of 600 committed field force in 600 countries, with a pipeline of 2600 products of which 1600 are registered and marketed. There is a 3300-person strong sales team in India distributing through 2400 stockists. The firm is now poised at a stage of rapid growth across geographies spanning Russia and CIS countries, China and South East Asia, Africa and Latin America, where the firm is rapidly emerging as the branded generic company of choice. Domestically, Sun Pharma, commands a 4% market share and is among the largest pharmaceutical companies in the country. The company is headquartered in Mumbai,
This combination of drugs saved many lives in Africa and also in other parts of the world . Cipla not just focus on its profits but also on to benefit the society . This initative of Cipla leads to the other foundation to join Cipla for the noble cause . But due to some patents agreement generic drugs withdrew from the market . TRIPS(Trade related aspects for intellectual property rights) agreement forced Cipla to withdrew the drugs from the market .
Mr. Ghanshyamdas Birla found no contradiction in pursuing business goals with the dedication of a saint, emerging as one of the foremost industrialists of pre-independence India. The principles by which he lived were immeresed by his grandson, Mr. Aditya Vikram Birla, the Group 's
Sri Awadhesh Bahadur did his post graduation in Commerce, JAIIB (CAIIB-1). Presently Sri Awadhesh Bahadur is holding the position of Manager (District Development), NABARD, Moradabad. He has been nominated on the Board on date 02.07.2009. Sri Arun Kumar Sri Arun Kumar Tyagi is the nominee Director representing Syndicate Bank on the Board. Educational Qualification of Sri Arun Kumar Tyagi is M.Sc.
Current trends in generic drug business which are the eight significant acquitions in 2006 for example Dr Reddy’s Laboratories outbid Teva (world largest generics company) to acquire Betapharm (Germany 4th largest), Ranbaxy to acquire Terapia (Romania’s largest generics company),Hospira to acquire Mayne Pharma, Barr Pharmaceutical to acquire Pliva, Mylan Labs to acquire Matrix, Stada Arzneimittel to acquire Hemopharm, Actavis to acquire Sindan. Spiraling healthcare cost and the healthcare expenditure = 3.1 – 5.0% of the GDP in year 2006 (Medical Cost Reference Guide, 2006). Government reduces expenditure by substitution affordable generics with prescription drugs which are the fastest rising component of health care. Trend observed in US and Japan are increasing use of
1.1 INTRODUCTION OF THE COMPANY The Aditya Birla Group is an Indian multinational conglomerate named after Aditya Vikram Birla, headquartered in the Aditya Birla Centre in Worli, Mumbai, India. It operates in 40 countries with more than 120,000 employees worldwide .The group was founded by Seth Shiv Narayan Birla in 1857. The group started its career in sectors such as viscose staple fiber, metals, cement (largest in India), viscose filament yarn, branded apparel, carbon black, chemicals, fertilizers, insulators, financial services, telecom (third largest in India), BPO and IT services. The Birla family is a family connected with the industrial and social history of India. The main branch of the Birla family are descendants of Seth Shobharam, grandson of Seth Bhudharmal a member of the Maheshwari Marwari community from Pilani in the westerly state of Rajasthan .